ClinicalTrials.gg

Program

stapokibart

Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.

Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.

Furthest: phase 3, since Feb 17, 202229 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences246 open or runningphase 3since Feb 17, 2022Mar 12, 2021Feb 2027phase 3 · NCT07106372
Chengdu Kangnuoxing Biopharma,Inc.33 open or runningphase 3since Sep 30, 2025Sep 30, 2025Dec 2026phase 3 · NCT07678931
CSPC Pharmaceutical Group22 open or runningphase 3since Feb 27, 2023Feb 27, 2023Apr 29, 2032phase 3 · NCT06547333

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Mar 12, 2021.

  1. Nov 29, 2023Phase 2 study in Dermatitis, AtopicKeymed Biosciences · NCT06162507 · 24 enrolled · China
  2. Nov 29, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06161090 · 33 enrolled · China
  3. Dec 4, 2023Phase 2 study in Rhinitis, Allergic, SeasonalKeymed Biosciences · NCT06171074 · 100 planned · China
  4. Dec 5, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06171048 · 236 planned · China
  5. Feb 18, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06277765 · 180 enrolled · China
  6. May 16, 2024Phase 3 study in Prurigo NodularisKeymed Biosciences · NCT06424470 · 200 enrolled · China
  7. Jul 2, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06495229 · 180 enrolled · China
  8. Jul 24, 2024Phase 2 study in Rhinitis, AllergicKeymed Biosciences · NCT06525597 · 120 planned · China
  9. Aug 7, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333 · 884 planned
  10. Apr 30, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06956196 · 240 planned · China
  11. Aug 5, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372 · 240 planned · China
  12. Sep 30, 2025Chengdu Kangnuoxing Biopharma,Inc.'s first study: phase 3 study in Pemphigoid, BullousNew to Chengdu Kangnuoxing Biopharma,Inc.Chengdu Kangnuoxing Biopharma,Inc. · NCT07210554 · 200 planned · China
  13. May 21, 2026Phase 2 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07617324 · 15 planned · China
  14. Jun 25, 2026Phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931 · 136 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931
  2. Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372
  3. Mar 27, 2028Primary completion: phase 3 study in Pemphigoid, BullousChengdu Kangnuoxing Biopharma,Inc. · NCT07210554
  4. Apr 29, 2032Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07678931Rhinitis, Allergic, Seasonal · China3RecruitingChengdu Kangnuoxing Biopharma,Inc.Dec 2026136
NCT07617324Rhinitis, Allergic, Seasonal · China2Not yet recruitingChengdu Kangnuoxing Biopharma,Inc.Oct 202615
NCT07210554Pemphigoid, Bullous · China3Not yet recruitingChengdu Kangnuoxing Biopharma,Inc.Mar 27, 2028200
NCT07106372Dermatitis, Atopic · China3Not yet recruitingKeymed BiosciencesFeb 2027240
NCT06956196Dermatitis, Atopic · China3Not yet recruitingKeymed BiosciencesMay 2026240
NCT06547333Pulmonary Disease, Chronic Obstructive3Not yet recruitingCSPC Pharmaceutical GroupApr 29, 2032884
NCT06525597Rhinitis, Allergic · China2RecruitingKeymed BiosciencesOct 30, 2025120
NCT06495229Dermatitis, Atopic · China3Active, not recruitingKeymed BiosciencesAug 30, 2026180
NCT06424470Prurigo Nodularis · China3CompletedKeymed BiosciencesFeb 11, 2026200
NCT06277765Dermatitis, Atopic · China3CompletedKeymed BiosciencesJan 23, 2025180
NCT06171048Healthy · China1Not yet recruitingKeymed BiosciencesApr 30, 2025236
NCT06171074Rhinitis, Allergic, Seasonal · China2Not yet recruitingKeymed BiosciencesMar 30, 2025100
NCT06162507Dermatitis, Atopic · China2CompletedKeymed BiosciencesJul 4, 202424
NCT06161090Healthy · China1CompletedKeymed BiosciencesJan 13, 202033
NCT06116565Dermatitis, Atopic · China2CompletedKeymed BiosciencesNov 26, 2025263
NCT05908721Rhinitis, Allergic · China2CompletedKeymed BiosciencesDec 10, 2023100
NCT05908032Rhinitis, Allergic · China3CompletedKeymed BiosciencesDec 4, 2023108
NCT05761028Moderate to Severe Asthma · China3RecruitingCSPC Pharmaceutical GroupMay 2032600
NCT05715320Dermatitis, Atopic · China2CompletedKeymed BiosciencesJul 18, 2024160
NCT05702450Healthy · China1CompletedKeymed BiosciencesJul 26, 2023240
NCT05579925Dermatitis, Atopic · China2CompletedKeymed BiosciencesJul 28, 202324
NCT05452343Chronic Pruritus of Unknown Origin2UNKNOWNKeymed BiosciencesMar 1, 202450
NCT05265923Dermatitis, Atopic · China3CompletedKeymed BiosciencesOct 31, 2023500
NCT05186909Asthma · China2CompletedKeymed BiosciencesSep 13, 202352
NCT05131464Chronic Rhinosinusitis With Nasal Polyps · China2CompletedKeymed BiosciencesJan 31, 202446
NCT04893707Dermatitis, Atopic · China2CompletedKeymed BiosciencesFeb 3, 2023127
NCT04893941Moderate-to-severe Atopic Dermatitis · China2CompletedKeymed BiosciencesJan 22, 202139
NCT04805411Dermatitis, Atopic · China2CompletedKeymed BiosciencesNov 8, 2021120
NCT04805398Disease · China2CompletedKeymed BiosciencesMar 18, 202256

How it is read

Names in the registry

  • “CM310”, 22 entries
  • “Stapokibart”, 2 entries
  • “Stapokibart injection”, 2 entries
  • “Stapokibatrt”, 2 entries
  • “Stapokibart Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.